ReviewPharmaceuticals (Basel, Switzerland)2018
TNBC Challenge: Oligonucleotide Aptamers for New Imaging and Therapy Modalities.
Review in Pharmaceuticals (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 52 citations in OpenAlex.
- Inhibition of MCCC2 Impedes TNBC Progression by Downregulating Leucine Metabolism-Dependent mTOR Signaling.Breast cancer (Dove Medical Press) · 2026Article
- Sono-triggered endoplasmic reticulum-targeted ROS burst silencing CD300ld to alleviate polymorphonuclear myeloid-derived suppressor cells for breast cancer treatment.Journal of nanobiotechnology · 2025Article
- Advancing targeted combination chemotherapy in triple negative breast cancer: nucleolin aptamer-mediated controlled drug release.Journal of translational medicine · 2024Article
- Nanoparticle-Mediated Immunotherapy in Triple-Negative Breast Cancer.ACS biomaterials science & engineering · 2024Review
- Article
- Aptamer-Based Strategies to Boost Immunotherapy in TNBC.Cancers · 2023Review
- Tumor Microenvironment Responsive Nanomicelle with Folic Acid Modification Co-Delivery of Doxorubicin/Shikonin for Triple Negative Breast Cancer Treatment.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Article
- Silencing TRAIP suppresses cell proliferation and migration/invasion of triple negative breast cancer via RB-E2F signaling and EMT.Cancer gene therapy · 2023Article
- Aptamer-Functionalized Nanoparticles Mediate PD-L1 siRNA Delivery for Effective Gene Silencing in Triple-Negative Breast Cancer Cells.Pharmaceutics · 2022Article
- PBX3-activated DLG1-AS1 can promote the proliferation, invasion, and migration of TNBC cells by sponging miR-16-5p.Molecular therapy oncolytics · 2022Article
- Research on correlations of miR-585 expression with progression and prognosis of triple-negative breast cancer.Clinical and experimental medicine · 2022Article
- Optimization of Short RNA Aptamers for TNBC Cell Targeting.International journal of molecular sciences · 2022Article
- Profiling Cancer Cells by Cell-SELEX: Use of Aptamers for Discovery of Actionable Biomarkers and Therapeutic Applications Thereof.Pharmaceutics · 2021Review
- Optimizing cisplatin delivery to triple-negative breast cancer through novel EGFR aptamer-conjugated polymeric nanovectors.Journal of experimental & clinical cancer research : CR · 2021Article
- Improving Breast Cancer Treatment Specificity Using Aptamers Obtained by 3D Cell-SELEX.Pharmaceuticals (Basel, Switzerland) · 2021Article
- VEGFR2 inhibition hampers breast cancer cell proliferationCancer biology & medicine · 2021Article
- Prognostic Significance of CCNB2 Expression in Triple-Negative Breast Cancer.Cancer management and research · 2021Article
- Aptamers and antibodies: rivals or allies in cancer targeted therapy?Exploration of targeted anti-tumor therapy · 2021Review
- Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer.Journal of experimental & clinical cancer research : CR · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Compared to other breast cancers, triple-negative breast cancer (TNBC) usually affects younger patients, is larger in size, of higher grade and is biologically more aggressive. To date, conventional cytotoxic chemotherapy remains the only available treatment for TNBC because it lacks expression of the estrogen receptor (ER), progesterone receptor (PR) and epidermal growth factor receptor 2 (HER2), and no alternative targetable molecules have been identified so far. The high biological and clinical heterogeneity adds a further challenge to TNBC management and requires the identification of new biomarkers to improve detection by imaging, thus allowing the specific treatment of each individual TNBC subtype. The Systematic Evolution of Ligands by EXponential enrichment (SELEX) technique holds great promise to the search for novel targetable biomarkers, and aptamer-based molecular approaches have the potential to overcome obstacles of current imaging and therapy modalities. In this review, we highlight recent advances in oligonucleotide aptamers used as imaging and/or therapeutic agents in TNBC, discussing the potential options to discover, image and hit new actionable targets in TNBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.